Bird Thomas D
Seattle VA Medical CenterDepartments of Neurology and MedicineUniversity of WashingtonSeattle, Washington
NOTE: THIS PUBLICATION HAS BEEN RETIRED. THIS ARCHIVAL VERSION IS FOR HISTORICAL REFERENCE ONLY, AND THE INFORMATION MAY BE OUT OF DATE.
-related hereditary motor and sensory neuropathy (-HMSN) is a peripheral neuropathy (also known as a subtype of Charcot-Marie-Tooth disease) that typically affects the lower extremities earlier and more severely than the upper extremities. As the neuropathy progresses, the distal upper extremities also become severely affected. Proximal muscles can also become weak. Age at onset ranges from infancy to early childhood. In most cases, disease progression causes disabilities within the first or second decade of life. At the end of the second decade, most individuals are wheelchair bound. Disease progression varies considerably even within the same family. The neuropathy can be either of the demyelinating type with reduced nerve conduction velocities or the axonal type with normal nerve conduction velocities. Vocal cord paresis is common. Intelligence is normal. Life expectancy is usually normal, but on occasion may be reduced because of secondary complications.
DIAGNOSIS/TESTING: Diagnosis of -HMSN is based on clinical findings and confirmed by detection on molecular genetic testing of either biallelic pathogenic variants in in those with autosomal recessive inheritance or a heterozygous pathogenic variant in those with autosomal dominant inheritance.
Treatment is symptomatic and involves evaluation and management by a multidisciplinary team that includes neurologists, physiatrists, orthopedic surgeons, and physical and occupational therapists. Treatment may include: daily heel cord stretching exercises to prevent Achilles tendon shortening, ankle/foot orthoses, orthopedic surgery, forearm crutches or canes, wheelchairs, treatment of musculoskeletal pain with acetaminophen or nonsteroidal anti-inflammatory agents, and career and employment counseling. : Regular evaluation by the multidisciplinary team to determine neurologic status and functional disability. Drugs and medications known to cause nerve damage; obesity.
-HMSN is usually inherited in an autosomal recessive (AR) manner; autosomal dominant (AD) inheritance is also observed. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives is possible once the pathogenic variants in an affected family member have been identified. Offspring of an individual with AD -HMSN have a 50% risk of inheriting the pathogenic variant from their affected parent. Prenatal testing for pregnancies at increased risk for -HMSN and preimplantation genetic testing are possible for families in which the pathogenic variant(s) have been identified.
注意:本出版物已停用。此存档版本仅用于历史参考,信息可能过时。
-相关遗传性运动和感觉神经病(-HMSN)是一种周围神经病(也称为夏科-马里-图斯病的一种亚型),通常下肢比上肢更早且更严重地受到影响。随着神经病进展,远端上肢也会受到严重影响。近端肌肉也可能变弱。发病年龄从婴儿期到幼儿期不等。在大多数情况下,疾病进展会在生命的第一个或第二个十年内导致残疾。在第二个十年结束时,大多数人需要依靠轮椅行动。即使在同一家族中,疾病进展也有很大差异。神经病可以是脱髓鞘型,神经传导速度降低,也可以是轴索性,神经传导速度正常。声带麻痹很常见。智力正常。预期寿命通常正常,但偶尔可能因继发并发症而缩短。
诊断/检测:-HMSN的诊断基于临床发现,并通过分子基因检测得到证实,对于常染色体隐性遗传的患者检测双等位基因致病变异,对于常染色体显性遗传的患者检测杂合致病变异。
治疗是对症治疗,由包括神经科医生、物理医学与康复医生、骨科医生以及物理治疗师和职业治疗师在内的多学科团队进行评估和管理。治疗可能包括:每日进行跟腱伸展运动以防止跟腱缩短、踝/足矫形器、骨科手术、前臂拐杖或手杖、轮椅、用对乙酰氨基酚或非甾体类抗炎药治疗肌肉骨骼疼痛,以及职业和就业咨询。定期由多学科团队进行评估以确定神经状态和功能残疾情况。已知会导致神经损伤的药物和药物;肥胖。
-HMSN通常以常染色体隐性(AR)方式遗传;也观察到常染色体显性(AD)遗传。在受孕时,受影响个体的每个兄弟姐妹有25%的机会受到影响,50%的机会成为无症状携带者,25%的机会未受影响且不是携带者。一旦确定了受影响家庭成员中的致病变异,就可以对有风险的亲属进行携带者检测。常染色体显性-HMSN个体的后代有50%的风险从其受影响的父母那里继承致病变异。对于已确定致病变异的家庭,对于-HMSN风险增加的妊娠可进行产前检测以及植入前基因检测。